Skip To Main Content
Barbara J. Flynn on Muck Rack

Barbara J. Flynn

As seen in: Nature, Daily Express, Science Magazine, Scottish Daily Record, BioRxiv, Cell Reports, Cell Press, Times Union (Albany), International Journal of Physical Distribution and Logistics Management
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara J.

Contact Barbara J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Anti-malaria antibody engineering broadens recognition motifs and reveals new homotypic interactions that enhance protective breadth

|
By Prabhanshu Tripathi, Yevel Flores-Garcia, Bharat Madan, Gene Lee, Ahmed Fahad, Haotian Lei, I-Ting Teng, Nicholas K. Hurlburt, Barbara J. Flynn, Marie Pancera, Kazutoyo Miura, Tongqing Zhou, Azza H Idris, Fidel Zavala, Robert A. Seder, Peter D. Kwong, Brandon J. DeKosky, Jihwan Chun
| Nature Verified
Abstract The monoclonal antibody L9 mediates high-level protection against malaria in children for up to 6 months in Africa. L9 preferentially binds with high affinity to a triplicate of NVDP-minor repeats on the P. falciparum circumsporozoite protein (PfCSP). Here, we sought to improve the affinity of L9 to enhance protection against rare strains with two spatially separated minor repeats or a single minor repeat.
Open in Who Shared Issue with article?

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

|
By Juan I. Moliva, Shayne F. Andrew, Barbara J. Flynn, Danielle Wagner
| BioRxiv
Abstract SARS-CoV-2 continues to pose a global threat, and current vaccines, while effective against severe illness, fall short in preventing transmission. To address this challenge, there's a need for vaccines that induce mucosal immunity and can rapidly control the virus.
Open in Who Shared Issue with article?

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

|
By Matthew Gagne, Barbara J. Flynn, Shayne F. Andrew, Dillon R. Flebbe
| BioRxiv
Abstract Waning immunity and continued virus evolution have limited the durability of protection from symptomatic infection mediated by intramuscularly (IM)-delivered mRNA vaccines against COVID-19 although protection from severe disease remains high. Mucosal vaccination has been proposed as a strategy to increase protection at the site of SARS-CoV-2 infection by enhancing airway immunity, potentially reducing rates of infection and transmission.
Open in Who Shared Issue with article?
See all 8 licensed articles (10 Total)